150 related articles for article (PubMed ID: 36785917)
21. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
Vasen HF; Gruis NA; Frants RR; van Der Velden PA; Hille ET; Bergman W
Int J Cancer; 2000 Sep; 87(6):809-11. PubMed ID: 10956390
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic carcinoma in carriers of a specific 19 base pair deletion of CDKN2A/p16 (p16-leiden).
de vos tot Nederveen Cappel WH; Offerhaus GJ; van Puijenbroek M; Caspers E; Gruis NA; De Snoo FA; Lamers CB; Griffioen G; Bergman W; Vasen HF; Morreau H
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3598-605. PubMed ID: 14506146
[TBL] [Abstract][Full Text] [Related]
23. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
[TBL] [Abstract][Full Text] [Related]
24. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
25. Pancreatic cancer-associated gene polymorphisms in a nation-wide cohort of p16-Leiden germline mutation carriers; a case-control study.
Potjer TP; van der Stoep N; Houwing-Duistermaat JJ; Konings IC; Aalfs CM; van den Akker PC; Ausems MG; Dommering CJ; van der Kolk LE; Maiburg MC; Spruijt L; Wagner A; Vasen HF; Hes FJ
BMC Res Notes; 2015 Jun; 8():264. PubMed ID: 26111702
[TBL] [Abstract][Full Text] [Related]
26. Functional CDKN2A assay identifies frequent deleterious alleles misclassified as variants of uncertain significance.
Kimura H; Paranal RM; Nanda N; Wood LD; Eshleman JR; Hruban RH; Goggins MG; Klein AP; ; Roberts NJ
Elife; 2022 Jan; 11():. PubMed ID: 35001868
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
Levink IJM; Klatte DCF; Hanna-Sawires RG; Vreeker GCM; Ibrahim IS; van der Burgt YEM; Overbeek KA; Koopmann BDM; Cahen DL; Fuhler GM; Wuhrer M; Bonsing BA; Tollenaar RAEM; Vleggaar FP; Vasen HFA; van Leerdam ME; Bruno MJ; Mesker WE
Pancreatology; 2022 May; 22(4):497-506. PubMed ID: 35414481
[TBL] [Abstract][Full Text] [Related]
28. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
29. EUS-based Pancreatic Cancer Surveillance in
Katona BW; Long JM; Ahmad NA; Attalla S; Bradbury AR; Carpenter EL; Clark DF; Constantino G; Das KK; Domchek SM; Dudzik C; Ebrahimzadeh J; Ginsberg GG; Heiman J; Kochman ML; Maxwell KN; McKenna DB; Powers J; Shah PD; Wangensteen KJ; Rustgi AK
Cancer Prev Res (Phila); 2021 Nov; 14(11):1033-1040. PubMed ID: 34341011
[TBL] [Abstract][Full Text] [Related]
30. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
31. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
Nishiwada S; Sho M; Banwait JK; Yamamura K; Akahori T; Nakamura K; Baba H; Goel A
Gastroenterology; 2020 Aug; 159(2):562-574. PubMed ID: 32376411
[TBL] [Abstract][Full Text] [Related]
32. Well-differentiated Pancreatic Neuroendocrine Tumor in a Patient With Familial Atypical Multiple Mole Melanoma Syndrome (FAMMM).
Noë M; Hackeng WM; de Leng WWJ; Vergeer M; Vleggaar FP; Morsink FHM; Wood LD; Hruban RH; Offerhaus GJA; Brosens LAA
Am J Surg Pathol; 2019 Sep; 43(9):1297-1302. PubMed ID: 31261289
[TBL] [Abstract][Full Text] [Related]
33. Reduced retinoids and retinoid receptors' expression in pancreatic cancer: A link to patient survival.
Bleul T; Rühl R; Bulashevska S; Karakhanova S; Werner J; Bazhin AV
Mol Carcinog; 2015 Sep; 54(9):870-9. PubMed ID: 24729540
[TBL] [Abstract][Full Text] [Related]
34. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance.
Katona BW; Klute K; Brand RE; Everett JN; Farrell JJ; Hawthorne K; Kaul V; Kupfer SS; Paiella S; Simeone DM; Sussman DA; Zogopoulos G; Lucas AL; Kastrinos F;
Cancer Prev Res (Phila); 2023 Jun; 16(6):343-352. PubMed ID: 37259800
[TBL] [Abstract][Full Text] [Related]
35. Surveillance for pancreatic cancer in high-risk individuals.
Konings ICAW; Canto MI; Almario JA; Harinck F; Saxena P; Lucas AL; Kastrinos F; Whitcomb DC; Brand RE; Lachter J; Malleo G; Paiella S; Syngal S; Saltzman JR; Stoffel EM; van Hooft JE; Hruban RH; Poley JW; Fockens P; Goggins MG; Bruno MJ;
BJS Open; 2019 Oct; 3(5):656-665. PubMed ID: 31592073
[TBL] [Abstract][Full Text] [Related]
36. Gene-Level Associations in Patients With and Without Pathogenic Germline Variants in
Astiazaran-Symonds E; Graham C; Kim J; Tucker MA; Ingvar C; Helgadottir H; Pastorino L; van Doorn R; Sampson JN; Zhu B; Bruno W; Queirolo P; Fornarini G; Sciallero S; Carter B; Hicks B; Hutchinson A; Jones K; Stewart DR; Chanock SJ; Freedman ND; Landi MT; Höiom V; Puig S; Gruis N; Yang XR; Ghiorzo P; Goldstein AM
JCO Precis Oncol; 2022 Nov; 6():e2200145. PubMed ID: 36409970
[TBL] [Abstract][Full Text] [Related]
37. [Will molecular diagnostics become established in pancreatic pathology?].
Sipos B; Sperveslage J
Pathologe; 2013 Nov; 34 Suppl 2():214-20. PubMed ID: 24196616
[TBL] [Abstract][Full Text] [Related]
38. Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.
Christodoulou E; Visser M; Potjer TP; van der Stoep N; Rodríguez-Girondo M; van Doorn R; Gruis N
Fam Cancer; 2019 Oct; 18(4):439-444. PubMed ID: 31203567
[TBL] [Abstract][Full Text] [Related]
39. Mutant Kras- and p16-regulated NOX4 activation overcomes metabolic checkpoints in development of pancreatic ductal adenocarcinoma.
Ju HQ; Ying H; Tian T; Ling J; Fu J; Lu Y; Wu M; Yang L; Achreja A; Chen G; Zhuang Z; Wang H; Nagrath D; Yao J; Hung MC; DePinho RA; Huang P; Xu RH; Chiao PJ
Nat Commun; 2017 Feb; 8():14437. PubMed ID: 28232723
[TBL] [Abstract][Full Text] [Related]
40. Integrated Genomic and Immunophenotypic Classification of Pancreatic Cancer Reveals Three Distinct Subtypes with Prognostic/Predictive Significance.
Wartenberg M; Cibin S; Zlobec I; Vassella E; Eppenberger-Castori S; Terracciano L; Eichmann MD; Worni M; Gloor B; Perren A; Karamitopoulou E
Clin Cancer Res; 2018 Sep; 24(18):4444-4454. PubMed ID: 29661773
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]